On July 6, 2022, the Food and Drug Administration (FDA) revised the Emergency Use Authorization for COVID-19 treatment Paxlovid. Under the new authorization, state-licensed pharmacists can now prescribe Paxlovid to eligible patients, amending the previous authorization that required an examination and a prescription from a licensed physician before pharmacists could dispense the treatment.

The FDA has now authorized pharmacists to prescribe Paxlovid to treat COVID-19 in eligible patients. But is there still more to be done?

Hear from Senior Vice President and General Manager of EnlivenHealth™ Danny Sanchez on the expanding role of pharmacists this National Pharmacist Day.

Medicare enrollments skyrocket right after the Thanksgiving holiday. Is your pharmacy prepared for the surge of Medicare patients needing enrollment help?

For many Medicare patients, a Medicare Advantage plan might be a better fit than a standalone PDP. Which ones? Read the article to find out.

Blake Wiseman, owner of J&R Pharmacy, explains how applying the DIR mitigation by migration strategy during Open Enrollment has helped him tackle DIR fees.

This Medicare Open Enrollment is the perfect opportunity to lower your DIR Fees. Here are 6 things every pharmacy should know about DIR Fees this fall.

Having the option of a plan with no DIR fees creates a win-win situation where both the patient and the pharmacy benefit from a plan change.

DIR fees can mystify even the best pharmacists. Let’s shed some light on DIR fees, so you’re ready to fight back with our proven tactics.

Medicare Open Enrollment can be a make-or-break time for pharmacies. Here's why FDS Amplicare chose HealthPlanOne to help Match users help their patients.

 

Four ways pharmacists can help patients during the Medicare Open Enrollment period, and the Amplicare tools to support them.